On this episode of PSPod, Drs. Lokesh Jain, Larissa Wenning, and Nitin Mehrotra from Merck discuss the important role model-informed drug development (MIDD) will play in the successful implementation of PDUFA VI. This discussion is based on their Perspective article “PDUFA VI: It’s Time to Unleash the Full Potential of Model-Informed Drug Development” which published in the January 2019 issue of PSP. The article is available here.
Tagged: Drug Development
On today’s episode, Mike Smith from Pfizer, Justin Wilkins from Occams, and Amy Cheung from AstraZeneca discuss “Thoughtflow”, a set of standards compiled by the DDMoRe consortium to help facilitate the capture, storage, and reporting of knowledge in the context of MID3, as well as to support reproducibility.
In this episode, Drs. Scott Marshall from Pfizer, Sandra Visser from Merck, and Amy Cheung from AstraZeneca discuss “Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation”: their White Paper published in the March 2016 issue of PSP. You can get free access the White Paper by clicking here.